Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not

Published:2020-12 Issue: Volume:22 Page:61-73
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Hemminki Otto^ORCID,Perlis Nathan,Bjorklund Johan,Finelli Antonio,Zlotta Alexandre R.,Hemminki Akseli

Funder

Biomedicum Helsinki Foundation

Finska läkaresällskapet

Jane and Aatos Erkko Foundation

HUCH Research Funds

Sigrid Juselius Foundation

Finnish Cancer Organizations

University of Helsinki

Publisher

Elsevier BV

Subject

Urology

Reference77 articles.

1. Immunotherapy for advanced renal cell cancer;Coppin;Cochrane Database Syst Rev,2005

2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

3. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer;Bukowski;Am J Clin Oncol,2007

4. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial;Escudier;J Clin Oncol,2009

5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High accuracy discriminant analysis of preparation from 22 commercial antibodies based on UV spectroscopy combined with chemometrics;Microchemical Journal;2024-10

2. H2 antihistamines: May be useful for combination therapies in cancer?;Biochemical Pharmacology;2024-05

3. Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiology;Scientific Reports;2024-04-23

4. Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century;Cancers;2023-05-16

5. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment;Nature Reviews Urology;2023-03-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3